ESC Congress 2022, the annual meeting of the European Society of Cardiology, was jam-packed with eye-opening new research from many of the leading voices in cardiovascular and vascular medicine. These six sessions were just some of the weekend's many highlights. 

A two-medication strategy after CABG surgery reduces the risk that grafts will fail, but it also increases the risk of serious bleeding. As one surgeon said, "the benefit comes at a price.”

A new paper published in Academic Radiology highlights some of the key clinical education lessons derived from the many disruptions to radiology rotations during the height of COVID. 

Adoption of PSMA-PET has been swift because it can significantly improve prostate cancer detection and treatment. SNMMI President Munir Ghesani, MD, explains how.

Elderly patients are often not eligible for oral anticoagulant therapy due to the risk of bleeding events or other adverse outcomes. A very low dose of edoxaban, however, appears to be a safe treatment option, even for especially frail patients.

"We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic," says Moderna CEO Stéphane Bancel.

A care team with the Sanger Heart & Vascular Institute has shared details about its recent successes in TMVR and TAVR. Cardiologist Michael Rinaldi, MD, highlighted the importance of having "a coordinated team of specialists with expertise in treating valve diseases."

The new findings, presented during ESC Congress 2022 and published in the New England Journal of Medicine, suggest that prescribing these new-look pills to heart patients could boost outcomes while also improving medication adherence.